Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study

Blood (2024) 144 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2024-209043

Published: 2024

Journal Articles

Acute Leukaemia in Pregnancy: A Systematic Review of Maternal and Fetal Outcomes

Wai Yee Jin, Giselle Kidson-Gerber, Antonia Shand, Antoinette Anazodo, Matthew Greenwood, Pietro R. Di Ciaccio, Shane Gangatharan, Ashley Kate McEwan, Kirk Morris, Caroline Wilson, Rachael Rodgers, Nada Hamad

Blood (2024) 144 (Supplement 1): 2428.

https://doi.org/10.1182/blood-2024-199449

Published: 2024

Journal Articles

Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

Betty Gration, Sandra Ware, Georgina Calov, Mark Barrios, Anne Marie Watson, David Gottlieb, Matthew Greenwood, Stephen Robert Larsen, Jacinta Perram

Blood (2024) 144 (Supplement 1): 4952.

https://doi.org/10.1182/blood-2024-203096

Published: 2024

Journal Articles

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Blood (2024) 144 (Supplement 1): 211.

https://doi.org/10.1182/blood-2024-194384

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Blood (2023) 142 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2023-178473

Published: 2023

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2023-189762

Published: 2023

Journal Articles

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Blood (2022) 140 (Supplement 1): 8971–8972.

https://doi.org/10.1182/blood-2022-168568

Published: 2022

Journal Articles

Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study

Georgia Mills, Pietro R Di Ciaccio, Catherine Tang, Verity L Chadwick, Kylie D Mason, Belinda Campbell, Mohamed Shanavas, Kirk L Morris, Matthew Greenwood, Giselle Kidson-Gerber, Renee Eslick, Xavier Badoux, Costas K. Yannakou, Shane A Gangatharan, Nada Hamad

Blood (2021) 138 (Supplement 1): 4099.

https://doi.org/10.1182/blood-2021-152065

Published: 2021

Journal Articles

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, Mohamed Shanavas, Matthew Greenwood, Gareth P Gregory, Renee Eslick, Giselle Kidson-Gerber, Catherine Tang, Kirk L Morris, Portia Smallbone, Xavier Badoux, Michael J Shipton, Sean J McKeague, Jenna Langfield, Kathryn Goss, Nada Hamad

Blood (2021) 138 (Supplement 1): 882.

https://doi.org/10.1182/blood-2021-150538

Published: 2021

Journal Articles

Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index

Jacinta Perram, Eleni Mayson, Catherine Tang, Steven Tran, Donna Aarons, Anthony J Dodds, Keith Fay, Nada Hamad, David Ma, Sam Milliken, Barbara Withers, Matthew Greenwood, William S Stevenson, Christopher Kevin Arthur, Ian H Kerridge, John Moore

Blood (2021) 138 (Supplement 1): 3958.

https://doi.org/10.1182/blood-2021-147106

Published: 2021

Journal Articles

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Shaun Fleming, John Reynolds, Ashish Bajel, Nicola Venn, John Kwan, John Moore, David T Yeung, Nalini Pati, Michael F. Leahy, Joanna Nkyekyer, Emma Verner, Leanne Berkahn, Rosemary Sutton, Andrew H. Wei, Matthew Greenwood

Blood (2021) 138 (Supplement 1): 1234.

https://doi.org/10.1182/blood-2021-151826

Published: 2021

Journal Articles

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

Edward Abadir, Jad Othman, John Kwan, David J Gottlieb, Glen A Kennedy, Ashish Bajel, Richard Doocey, Travis Perera, Anne-Marie Watson, Peter G Bardy, Matthew Greenwood, David J. Curtis, Steven Tran, John Moore, Nada Hamad

Blood (2021) 138 (Supplement 1): 2929.

https://doi.org/10.1182/blood-2021-149939

Published: 2021

Journal Articles

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

John Moore, MB.BS, MD FRACP, FRCPA, John Kwan, MBBS,FRACP,FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ashish Bajel, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Steven Tran, BEng MBiomedE, Donna Aarons, B.Pharm, Nada Hamad, MB.BS, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-142131

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, David Gottlieb, MBBS, MD FRACP, FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Stephen R Larsen, MBBS PhDFRACP FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Simon Durrant, MBBS FRCP FRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Cameron Curley, MBBS, FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139057

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, David Ritchie, MB ChB, PhD FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Stephen R Larsen, MBBS PhDFRACP FRCPA, Andrew Spencer, Travis Perera, MB ChB, FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Simon Durrant, MBBS FRCP FRCPath, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Richard Doocey, MB ChB, FRACP, FRCPA, Hugh J. Goodman, FRACP, Ian H. Kerridge, FRACP FRCPA MPhil BA, Christopher Arthur, Cameron Curley, MBBS, FRACP, FRCPA, Caroline Stewart, Kenneth P. Micklethwaite, MBBS, PhD FRACP, FRCPA, Jennifer Collins, Julian Cooney, FRACP,FRCPA,MBBS,, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139076

Published: 2020

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Blood (2019) 134 (Supplement_1): 5719.

https://doi.org/10.1182/blood-2019-126547

Published: 2019

NARROW

Health-Related Quality of Life in Adolescents and Young Adults Treated with Blinatumomab Consolidation for CD19+ Ph-Negative Acute Lymphoblastic Leukemia in the Australasian Lymphoma and Leukaemia Group (ALLG) ALL09 “Sublime” Study

Acute Leukaemia in Pregnancy: A Systematic Review of Maternal and Fetal Outcomes

Second Transplant Offers the Possibility of Long Term Graft-Versus-Host-Disease-Free Relapse-Free Survival

Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Outcomes for Allogeneic Stem Cell Transplantation in Secondary AML Are Inferior to De Novo AML and Are Independent of the Disease Risk Index

Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study

Peripheral Blood Haploidentical Allogeneic Stem Cell Transplantation in Older Adults with AML/MDS Demonstrates Excellent Long Term Overall Survival, Results from the Australasian Bone Marrow Transplant Recipient Registry

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study

Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

An Update of Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only